Works matching AU Nelander, Karin
Results: 15
Pharmacokinetics and Tolerability of the Novel Myeloperoxidase Inhibitor Mitiperstat in Healthy Japanese and Chinese Volunteers.
- Published in:
- Clinical Drug Investigation, 2024, v. 44, n. 11, p. 863, doi. 10.1007/s40261-024-01402-x
- By:
- Publication type:
- Article
Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 10, p. 895, doi. 10.1007/s40261-021-01078-7
- By:
- Publication type:
- Article
Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 551, doi. 10.1111/dom.16047
- By:
- Publication type:
- Article
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses.
- Published in:
- Pharmacology Research & Perspectives, 2024, v. 12, n. 2, p. 1, doi. 10.1002/prp2.1184
- By:
- Publication type:
- Article
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction.
- Published in:
- CTS: Clinical & Translational Science, 2021, v. 14, n. 3, p. 812, doi. 10.1111/cts.12859
- By:
- Publication type:
- Article
Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor.
- Published in:
- CTS: Clinical & Translational Science, 2018, v. 11, n. 3, p. 330, doi. 10.1111/cts.12546
- By:
- Publication type:
- Article
Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.
- Published in:
- Clinical Pharmacology in Drug Development, 2020, v. 9, n. 3, p. 411, doi. 10.1002/cpdd.756
- By:
- Publication type:
- Article
The effect of severe renal impairment on the pharmacokinetics, safety and tolerability of mitiperstat.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 12, p. 3212, doi. 10.1111/bcp.16205
- By:
- Publication type:
- Article
A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 9, p. 2180, doi. 10.1111/bcp.16131
- By:
- Publication type:
- Article
Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 4, p. 762, doi. 10.1111/bcp.13855
- By:
- Publication type:
- Article
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
- Published in:
- British Journal of Clinical Pharmacology, 2018, v. 84, n. 7, p. 1486, doi. 10.1111/bcp.13562
- By:
- Publication type:
- Article
On Exact Simulation of Markov Random Fields Using Coupling from the Past.
- Published in:
- Scandinavian Journal of Statistics, 1999, v. 26, n. 3, p. 395, doi. 10.1111/1467-9469.00156
- By:
- Publication type:
- Article
Rationale and design of ENDEAVOR: A sequential phase 2b–3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 9, p. 1696, doi. 10.1002/ejhf.2977
- By:
- Publication type:
- Article
Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants.
- Published in:
- Pharmacology Research & Perspectives, 2024, v. 12, n. 5, p. 1, doi. 10.1002/prp2.70029
- By:
- Publication type:
- Article
Prothrombin time is predictive of low plasma prothrombin concentration and clinical outcome in patients with trauma hemorrhage: analyses of prospective observational cohort studies.
- Published in:
- Scandinavian Journal of Trauma, Resuscitation & Emergency Medicine, 2017, v. 25, p. 1, doi. 10.1186/s13049-016-0332-2
- By:
- Publication type:
- Article